Base editing shows promise for treating sickle cell disease and beta thalassemia
Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia.
Stay updated with breaking news from Mitchell Weiss. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia.
A programmable gene editing technology called prime editing can correct the mutation that causes sickle cell disease, in a potentially curative approach.
If you think of Michelle Wu as the architect of Boston’s new city government, then Tiffany Chu ’10 might be the general contractor. As the chief of staff to Mayor Wu, Chu is in charge of figuring out how visions of urban transformation actually take shape. Take the Thursday afternoon in early February that found…
Prime-edited hematopoietic stem cells from sickle cell disease patients can engraft and help treat genetic blood disorders in mice.
New study from St. Jude Children's, MIT and Harvard shows a promising approach to treating sickle cell disease.